TRexBio prices $117M IPO, Nasdaq trading expected

TRexBio priced its initial public offering at $14.00 per share for 8,333,334 shares of common stock, expecting approximately $116.7 million in gross proceeds before underwriting discounts, commissions and other expenses. All shares are being offered by the company. Common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker TRXB. The offering is expected to close on October 13, 2026, subject to customary closing conditions, after a registration statement became effective on October 8, 2026. Underwriters hold a 30-day option to purchase up to 1,250,000 additional shares at the IPO price. J.P. Morgan, Evercore ISI, Cantor and Stifel are lead book-running managers, with Wedbush PacGrow as book-running manager. The South San Francisco clinical-stage biotechnology company develops immunoregulatory medicines for autoimmune and inflammatory diseases based on regulatory T-cell biology. Its lead candidate, TRB-061, is in a Phase 1b trial for atopic dermatitis, with topline data expected in mid-2027. Eli Lilly, TRexBio’s largest pre-IPO shareholder, indicated interest in increasing its stake to 19.9% after the IPO. No left-rated, center-rated or right-rated coverage was recorded. Available accounts do not dispute the share count, price, proceeds, ticker, close date or underwriter terms.